当前位置: 首页 >> 检索结果
291. SAPIEN 3 versus Myval transcatheter heart valves for transcatheter aortic valve implantation (COMPARE-TAVI 1): a multicentre, randomised, non-inferiority trial.
作者: Christian Juhl Terkelsen.;Philip Freeman.;Jordi Sanchez Dahl.;Troels Thim.;Bjarne Linde Nørgaard.;Nils Sofus Borg Mogensen.;Mariann Tang.;Ashkan Eftekhari.;Jonas Agerlund Povlsen.;Steen Hvitfeldt Poulsen.;Lars Pedersen.;Jakob Hjort.;Julia Ellert.;Evald Høj Christiansen.;Henrik Toft Sørensen.;Henrik Nissen.
来源: Lancet. 2025年405卷10487期1362-1372页
Transcatheter aortic valve implantation (TAVI) is a guideline-directed treatment for severe aortic stenosis and degenerated aortic bioprostheses. When new transcatheter heart valve (THV) platforms for TAVI are launched, they should be compared with best-in-practice contemporary THVs for their short-term and long-term performance. The COMPARE-TAVI 1 trial was designed to provide a head-to-head comparison of the SAPIEN 3 or SAPIEN 3 Ultra THVs and the Myval or Myval Octacor THVs.
292. The Lancet Commission on rethinking coronary artery disease: moving from ischaemia to atheroma.
作者: Sarah Zaman.;Jason H Wasfy.;Vikas Kapil.;Boback Ziaeian.;William A Parsonage.;Sira Sriswasdi.;Timothy J A Chico.;Davide Capodanno.;Róisín Colleran.;Nadia R Sutton.;Lei Song.;Nicole Karam.;Reecha Sofat.;Chiara Fraccaro.;Daniel Chamié.;Mirvat Alasnag.;Takayuki Warisawa.;Nieves Gonzalo.;Walid Jomaa.;Shamir R Mehta.;Elizabeth E S Cook.;Johan Sundström.;Stephen J Nicholls.;Leslee J Shaw.;Manesh R Patel.;Rasha K Al-Lamee.
来源: Lancet. 2025年405卷10486期1264-1312页 293. Durability and efficacy of solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, in adults with mixed dyslipidaemia (PROLONG-ANG3): a double-blind, randomised, placebo-controlled, phase 2 trial.
作者: Kausik K Ray.;Ena Oru.;Robert S Rosenson.;Jeremiah Jones.;Xiaosu Ma.;Jennie Walgren.;Axel Haupt.;Subodh Verma.;Daniel Gaudet.;Stephen J Nicholls.;Giacomo Ruotolo.
来源: Lancet. 2025年405卷10489期1594-1607页
Mixed dyslipidaemia, characterised by elevated concentrations of circulating triglycerides and LDL cholesterol (LDL-C), is associated with an increased risk of atherosclerotic cardiovascular disease. Solbinsiran, a GalNAc-conjugated small interfering RNA targeting hepatic angiopoietin-like protein 3 (ANGPTL3), reduced triglycerides and LDL-C concentrations in a phase 1 study. This study aimed to assess the durability and efficacy of solbinsiran in reducing concentrations of atherogenic lipoproteins in adults with mixed dyslipidaemia.
299. Efficacy and safety of clopidogrel versus aspirin monotherapy in patients at high risk of subsequent cardiovascular event after percutaneous coronary intervention (SMART-CHOICE 3): a randomised, open-label, multicentre trial.
作者: Ki Hong Choi.;Yong Hwan Park.;Jong-Young Lee.;Jin-Ok Jeong.;Chan Joon Kim.;Kyeong Ho Yun.;Han Cheol Lee.;Kiyuk Chang.;Mahn-Won Park.;Jang-Whan Bae.;Joon-Hyung Doh.;Byung Ryul Cho.;Hee-Yeol Kim.;Weon Kim.;Ung Kim.;Seung-Woon Rha.;Young Joon Hong.;Hyun-Jong Lee.;Sung Gyun Ahn.;Doo-Il Kim.;Jang Hyun Cho.;Sung Ho Her.;Doo Soo Jeon.;Seung Hwan Han.;Jin-Bae Lee.;Cheol Whan Lee.;Danbee Kang.;Joo Myung Lee.;Taek Kyu Park.;Jeong Hoon Yang.;Soo-Youn Lee.;Seung-Hyuk Choi.;Hyeon-Cheol Gwon.;Young Bin Song.;Joo-Yong Hahn.; .
来源: Lancet. 2025年405卷10486期1252-1263页
The optimal strategy for long-term antiplatelet maintenance for patients who underwent percutaneous coronary intervention (PCI) remains uncertain. This study aimed to compare the efficacy and safety of clopidogrel versus aspirin monotherapy in patients who completed a standard duration of dual antiplatelet therapy (DAPT) following PCI with drug-eluting stents.
300. Outcomes after fractional flow reserve-guided percutaneous coronary intervention versus coronary artery bypass grafting (FAME 3): 5-year follow-up of a multicentre, open-label, randomised trial.
作者: William F Fearon.;Frederik M Zimmermann.;Victoria Y Ding.;Kuniaki Takahashi.;Zsolt Piroth.;Albert H M van Straten.;Laszlo Szekely.;Giedrius Davidavičius.;Gintaras Kalinauskas.;Samer Mansour.;Rajesh Kharbanda.;Nikolaos Östlund-Papadogeorgos.;Adel Aminian.;Keith G Oldroyd.;Nawwar Al-Attar.;Nikola Jagic.;Jan-Henk E Dambrink.;Petr Kala.;Oskar Angerås.;Philip MacCarthy.;Olaf Wendler.;Filip Casselman.;Nils Witt.;Kreton Mavromatis.;Steven E S Miner.;Jaydeep Sarma.;Thomas Engstrøm.;Evald H Christiansen.;Pim A L Tonino.;Michael J Reardon.;Hisao Otsuki.;Yuhei Kobayashi.;Mark A Hlatky.;Kenneth W Mahaffey.;Manisha Desai.;Y Joseph Woo.;Alan C Yeung.;Nico H J Pijls.;Bernard De Bruyne.
来源: Lancet. 2025年405卷10488期1481-1490页
Long-term outcomes following percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) might be changing because of improved techniques and better medical therapy. This final prespecified analysis of the Fractional Flow Reserve (FFR) versus Angiography for Multivessel Evaluation (FAME) 3 trial aimed to reassess their comparative effectiveness at 5 years.
|